Burning rock announces the launch of china's first prospective interventional validation study on multi-cancer early detection - the prevent study

Chengdu, china, june 30, 2022 (globe newswire) -- burning rock biotech limited (nasdaq: bnr, the “company” or “burning rock”), a company focused on the application of next generation sequencing (ngs) technology in the field of precision oncology, today announced the launch of the prevent (a prospective multi-cancer early-detection and interventional) study, china's first prospective interventional study to evaluate the performance of burning rock's early cancer detection test, overc™, in the asymptomatic population. the study is expected to enroll 12,500 asymptomatic individuals, to evaluate the performance of the overc™ test in detecting 6 cancers (lung, liver, colorectal, esophageal, pancreatic and ovarian cancers). these 6 cancer types cover approximately 50% of china's total cancer incidence, and 62% of cancer mortality1.
BNR Ratings Summary
BNR Quant Ranking